Literature DB >> 11723085

Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes.

N Chaturvedi1, J H Fuller, M R Taskinen.   

Abstract

OBJECTIVE: Cardiovascular disease (CVD) is increased in patients with type 1 diabetes, but lipid and lipoprotein patterns remain favorable. In contrast, nephropathy is associated with an adverse distribution. We compared the associations and predictive power of lipid and lipoprotein disturbances with these complications. RESEARCH DESIGN AND METHODS: A nested case-control study from the EURODIAB cohort of 140 case subjects with evidence of at least one complication and 84 control subjects with no complications were analyzed. Conventional and unconventional lipid and lipoprotein fractions, including apolipoprotein (apo)-A1, lipoprotein (Lp)-A1, LpA1/A2, apoB, and LDL particle size were measured centrally.
RESULTS: CVD was only associated with increased LDL cholesterol (3.6 vs. 3.0 mmol/l, P = 0.02). In contrast, albuminuria was associated with elevated cholesterol, triglyceride, LDL, and apoB and with diminished LDL particle size. No disturbances in HDL and related lipoproteins were noted. In normoalbuminuric patients, CVD was not associated with any significant changes in lipids. CVD in macroalbuminuric patients was associated with increased triglyceride level (2.37 vs. 1.07 mmol/l, P = 0.001; P = 0.02 for CVD/albuminuria interaction) and LDL cholesterol (5.4 vs. 3.3 mmol/l, P = 0.005; P = 0.004 for interaction). Independent associations were observed for total cholesterol and for LDL particle size and albuminuria.
CONCLUSIONS: Abnormalities in lipid and lipoprotein disturbances are more closely related to albuminuria than to CVD in patients with type 1 diabetes. Measurement of conventional parameters provide sufficient risk information. ApoB and LDL particle size offer limited extra information. HDL metabolism remains undisturbed in the presence of complications. These changes reflect associations with glycemic control, which is the key to understanding lipid and lipoprotein disturbances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723085     DOI: 10.2337/diacare.24.12.2071

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

Review 1.  Cardiovascular disease risk in young people with type 1 diabetes.

Authors:  Janet K Snell-Bergeon; Kristen Nadeau
Journal:  J Cardiovasc Transl Res       Date:  2012-04-12       Impact factor: 4.132

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study.

Authors:  M T Schram; N Chaturvedi; C G Schalkwijk; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2005-02-04       Impact factor: 10.122

4.  Renal functional reserve in patients with Type 1 diabetes mellitus.

Authors:  Jelka Zaletel; Darko Cerne; Katarina Lenart; Sabine Zitta; Günther Jürgens; Willibald Estelberger; Andreja Kocijancic
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

5.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

Review 6.  Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes.

Authors:  Sowmya Krishnan; Kevin R Short
Journal:  J Cardiometab Syndr       Date:  2009

7.  Progression to microalbuminuria in patients with type 1 diabetes: a seven-year prospective study.

Authors:  Roberta A Cobas; Bráulio Santos; Pedro Cb da Silva; Ricardo Neves; Marilia B Gomes
Journal:  Diabetol Metab Syndr       Date:  2011-08-26       Impact factor: 3.320

8.  Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study).

Authors:  Ville-Petteri Mäkinen; Carol Forsblom; Lena M Thorn; Johan Wadén; Kimmo Kaski; Mika Ala-Korpela; Per-Henrik Groop
Journal:  Cardiovasc Diabetol       Date:  2009-10-06       Impact factor: 9.951

9.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

10.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death.

Authors:  Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela
Journal:  Mol Syst Biol       Date:  2008-02-12       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.